Download presentation
Presentation is loading. Please wait.
Published byMagdalene Hortense O’Brien’ Modified over 8 years ago
1
Pharmaceutical Industry R&D An inside-out look at trends and career opportunities Lots of promise but little delivered in the way of new drugs Vastly reduced work force in the Pharmaceutical R&D industry Or is it?
2
Eroom’s Law Pharmaceutical Research is in trouble Scannell et al Nat Rev Drug Discovery 11, 191 (2012) Drugs per billion US $
3
The easy stuff has been done Complexity growing exponentially Reimbursement for new drugs? Better is not always sufficient for insurance companies Lower acceptance of side effects – questioning approved drugs Bad press – some deserved and some not Pharma R&D IS a Challenging Career
4
Challenges Patent cliffs Exploding costs of drug discovery and development Much higher hurdles for approval for major indications Efficacy not enough – how is it better? And what does better mean? Quality of life, dosage,side affect profile Blockbuster strategy is dead Niche markets Orphan indications High failure (attrition) rate – have to cover cost of failures in pricing of successful drugs Generic competition Big Pharma moving more toward Development and away from Discovery
5
Need more students to go into the sciences What do we tell students about opportunities if they go into science? Students want an education which prepares them for a career – not unempolyment or under- employment I believe the opportunities are still plentiful if you understand the landscape Universal Concerns from Colleges,Universities, Faculty and Students
6
Changing Definitions Pharmaceutical Industry does not equal Big Pharma! The days of everything being in-house are long gone The Pharma industry is really a network of big companies, start- ups, contract research organizations (CRO’s), Academic labs, research institutes …….. Big Pharma is reinventing itself to be more nimble – more biotech-like
7
Changing Definitions Biotech today is not Biotech of the 20 th century Many biotechs have been swallowed up by large Pharma Days of biotechs seeing themselves as becoming fully integrated pharmaceutical companies is gone Most have a technology or compound they want to sell to large companies, use to attract a large company to buy them or become a specialty service provider. So Biotechs are really an integrated part of the Pharma Industry today – the source of much early Discovery research
8
Key elements of the “new” Pharma Industry CROs Diagnostic companies Over the counter manufacturers Generics manufacturers Medical device developers and manufacturers New age of bioelectronics Drug delivery companies
9
Opportunities are Growing Aging population More chronic indications Fewer people going into the sciences (or the needed sciences) Start ups are on the rise again As big pharma gets smaller CRO’s get bigger E.g. Covance has more people in R&D than GSK Outsourcing no longer automatically equates with shipping jobs to China and India
10
What’s Hot and What’s Not CROs Consortia Public private Flexibility PhD not as much a requirement as in the past Working internationally Project management
11
Bioelectronics Cell biology Stem cells Phenotypic screening Structural biology Science technologies of the year http://www.newsobserver.com/2014/01/05/3497863/science-magazine- picks-top-breakthroughs.html http://www.newsobserver.com/2014/01/05/3497863/science-magazine- picks-top-breakthroughs.html Crispr Cancer immunotherapy Bioinformatics Proteomics/chemoproteomics Biomarkers Synthetic biochemistry Not – traditional drug screening, animal models, natural products, doing everything in- house, doing one thing for your career, What’s Hot and What’s Not
14
http://www.addconsortium.org/
16
Beyond the Lab Medical writing Regulatory Affairs Clin ops Compliance QA Bus Dev (In-licensing and out-licensing) Business and Technical Operations Portfolio Management >85% of jobs in Pharma are outside traditional R&D but majority are people with science degrees
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.